ALS Association Wants More Commitment From the FDA

ALS Association Wants More Commitment From the FDA

297628

ALS Association Wants More Commitment From the FDA

In a response letter to The ALS Association, the U.S. Food and Drug Administration (FDA) has recognized the unmet therapeutic need of people with amyotrophic lateral sclerosis (ALS) and reaffirmed its commitment to the 2019 ALS clinical trial guidance. However, the agency did not provide any details about how it has implemented that guidance to date — a specific request made by the association shortly after hosting a virtual meeting with the FDA in May. The meeting was meant to…

You must be logged in to read/download the full post.